BioMarin sets gene therapy sights beyond hemophilia

On the cusp of having a marketed gene therapy for hemophilia, BioMarin is readying itself for the commercial challenges that lie ahead. The California biotech's CEO says he's assured patients and doctors will go for the therapy, despite a price tag that, at least in the U.S., is likely to fall in the range of $1 million to $3 million.